Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters
We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found...
Gespeichert in:
| Veröffentlicht in: | International journal of pharmaceutics 2006-06, Vol.316 (1), p.144-147 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 1 |
| container_start_page | 144 |
| container_title | International journal of pharmaceutics |
| container_volume | 316 |
| creator | Rubinstein, Israel Ikezaki, Hiroyuki Önyüksel, Hayat |
| description | We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1
nmol) administered by either routes normalizes MAP (
p
<
0.05). Maximal effect was observed within 10–20
min and lasted for 6
h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1
nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1
nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension. |
| doi_str_mv | 10.1016/j.ijpharm.2006.02.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19452379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517306001517</els_id><sourcerecordid>19452379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-b4d41d35c5edc341afea811d420c20b6b11e2ae9243caa22f321561c70b5b7703</originalsourceid><addsrcrecordid>eNqFkEFr3DAQhUVoSbZpfkKKLu3NW41kWd5TKSFtFgLtoe1VyPKY1WLLrsYObH99FdaQY-DBDNL3ZobH2C2ILQioPh-34TgdXBq2UohqK2RWfcE2UBtVqNJUb9hGKFMXGoy6Yu-IjiKDEtQlu4JK13mI2LBpH-fksvwBXc9dbDktjV9mF3FciPdhGmkc8tef_U8ex5Tb8A-JuzRjCvl9Ski0JOQhcprGuDr7Ez-cJsxUpPCE_OAGyg56z952rie8Wes1-_3t_tfdQ_H44_v-7utj4dVOzUVTtiW0SnuNrVcluA5dDdCWUngpmqoBQOlwJ0vlnZOyUxJ0Bd6IRjfGCHXNPp3nTmn8uyDNdgjkse_P51nYlVoqs8ugPoM-jUQJOzulMLh0siDsc9T2aNeo7XPUVsisOvs-rAuWZsD2xbVmm4GPK-DIu75LLvpAL5ypJUitMvflzGGO4ylgsuQDRo9tSOhn247hlVP-A8cuoqs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19452379</pqid></control><display><type>article</type><title>Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rubinstein, Israel ; Ikezaki, Hiroyuki ; Önyüksel, Hayat</creator><creatorcontrib>Rubinstein, Israel ; Ikezaki, Hiroyuki ; Önyüksel, Hayat</creatorcontrib><description>We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1
nmol) administered by either routes normalizes MAP (
p
<
0.05). Maximal effect was observed within 10–20
min and lasted for 6
h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1
nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1
nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2006.02.028</identifier><identifier>PMID: 16580160</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - pharmacology ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; Cricetinae ; Drug delivery ; DSPE-PEG ; Formulation ; General pharmacology ; Hypertension - drug therapy ; Hypertension - physiopathology ; Injections, Subcutaneous ; Intubation, Intratracheal ; Liposomes ; Male ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Sterically stabilized liposomes ; Vasoactive Intestinal Peptide - administration & dosage ; Vasoactive Intestinal Peptide - pharmacology ; Vasoactive Intestinal Peptide - therapeutic use</subject><ispartof>International journal of pharmaceutics, 2006-06, Vol.316 (1), p.144-147</ispartof><rights>2006 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-b4d41d35c5edc341afea811d420c20b6b11e2ae9243caa22f321561c70b5b7703</citedby><cites>FETCH-LOGICAL-c393t-b4d41d35c5edc341afea811d420c20b6b11e2ae9243caa22f321561c70b5b7703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2006.02.028$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17821253$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16580160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rubinstein, Israel</creatorcontrib><creatorcontrib>Ikezaki, Hiroyuki</creatorcontrib><creatorcontrib>Önyüksel, Hayat</creatorcontrib><title>Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1
nmol) administered by either routes normalizes MAP (
p
<
0.05). Maximal effect was observed within 10–20
min and lasted for 6
h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1
nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1
nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension.</description><subject>Animals</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cricetinae</subject><subject>Drug delivery</subject><subject>DSPE-PEG</subject><subject>Formulation</subject><subject>General pharmacology</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Injections, Subcutaneous</subject><subject>Intubation, Intratracheal</subject><subject>Liposomes</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Sterically stabilized liposomes</subject><subject>Vasoactive Intestinal Peptide - administration & dosage</subject><subject>Vasoactive Intestinal Peptide - pharmacology</subject><subject>Vasoactive Intestinal Peptide - therapeutic use</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFr3DAQhUVoSbZpfkKKLu3NW41kWd5TKSFtFgLtoe1VyPKY1WLLrsYObH99FdaQY-DBDNL3ZobH2C2ILQioPh-34TgdXBq2UohqK2RWfcE2UBtVqNJUb9hGKFMXGoy6Yu-IjiKDEtQlu4JK13mI2LBpH-fksvwBXc9dbDktjV9mF3FciPdhGmkc8tef_U8ex5Tb8A-JuzRjCvl9Ski0JOQhcprGuDr7Ez-cJsxUpPCE_OAGyg56z952rie8Wes1-_3t_tfdQ_H44_v-7utj4dVOzUVTtiW0SnuNrVcluA5dDdCWUngpmqoBQOlwJ0vlnZOyUxJ0Bd6IRjfGCHXNPp3nTmn8uyDNdgjkse_P51nYlVoqs8ugPoM-jUQJOzulMLh0siDsc9T2aNeo7XPUVsisOvs-rAuWZsD2xbVmm4GPK-DIu75LLvpAL5ypJUitMvflzGGO4ylgsuQDRo9tSOhn247hlVP-A8cuoqs</recordid><startdate>20060619</startdate><enddate>20060619</enddate><creator>Rubinstein, Israel</creator><creator>Ikezaki, Hiroyuki</creator><creator>Önyüksel, Hayat</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20060619</creationdate><title>Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters</title><author>Rubinstein, Israel ; Ikezaki, Hiroyuki ; Önyüksel, Hayat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-b4d41d35c5edc341afea811d420c20b6b11e2ae9243caa22f321561c70b5b7703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cricetinae</topic><topic>Drug delivery</topic><topic>DSPE-PEG</topic><topic>Formulation</topic><topic>General pharmacology</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Injections, Subcutaneous</topic><topic>Intubation, Intratracheal</topic><topic>Liposomes</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Sterically stabilized liposomes</topic><topic>Vasoactive Intestinal Peptide - administration & dosage</topic><topic>Vasoactive Intestinal Peptide - pharmacology</topic><topic>Vasoactive Intestinal Peptide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rubinstein, Israel</creatorcontrib><creatorcontrib>Ikezaki, Hiroyuki</creatorcontrib><creatorcontrib>Önyüksel, Hayat</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rubinstein, Israel</au><au>Ikezaki, Hiroyuki</au><au>Önyüksel, Hayat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2006-06-19</date><risdate>2006</risdate><volume>316</volume><issue>1</issue><spage>144</spage><epage>147</epage><pages>144-147</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1
nmol) administered by either routes normalizes MAP (
p
<
0.05). Maximal effect was observed within 10–20
min and lasted for 6
h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1
nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1
nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16580160</pmid><doi>10.1016/j.ijpharm.2006.02.028</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2006-06, Vol.316 (1), p.144-147 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19452379 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antihypertensive Agents - administration & dosage Antihypertensive Agents - pharmacology Antihypertensive Agents - therapeutic use Biological and medical sciences Blood Pressure - drug effects Cricetinae Drug delivery DSPE-PEG Formulation General pharmacology Hypertension - drug therapy Hypertension - physiopathology Injections, Subcutaneous Intubation, Intratracheal Liposomes Male Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Sterically stabilized liposomes Vasoactive Intestinal Peptide - administration & dosage Vasoactive Intestinal Peptide - pharmacology Vasoactive Intestinal Peptide - therapeutic use |
| title | Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intratracheal%20and%20subcutaneous%20liposomal%20VIP%20normalizes%20arterial%20pressure%20in%20spontaneously%20hypertensive%20hamsters&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Rubinstein,%20Israel&rft.date=2006-06-19&rft.volume=316&rft.issue=1&rft.spage=144&rft.epage=147&rft.pages=144-147&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2006.02.028&rft_dat=%3Cproquest_cross%3E19452379%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19452379&rft_id=info:pmid/16580160&rft_els_id=S0378517306001517&rfr_iscdi=true |